Validation of the 2018 NCCN Prostate Cancer Risk Classification among 2,715 Patients Treated with Low Dose Rate I-125 Brachytherapy

被引：0
|
作者：
Tom, M. C. [1 ]
Reddy, C. A. [1 ]
Smile, T. [1 ]
Zhang, R. X. [2 ]
Ciezki, J. P. [1 ]
Stephans, K. L. [1 ]
Mian, O. Y. [1 ]
Klein, E. A. [3 ]
Campbell, S. [3 ]
Ulchaker, J. [3 ]
Angermeier, K. [3 ]
Tendulkar, R. D. [1 ]
机构：
[1] Cleveland Clin, Dept Radiat Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA
[3] Cleveland Clin, Glickman Urol Inst, Cleveland, OH 44106 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2019.06.1776
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2710
引用
收藏
页码：E310 / E310
页数：1
相关论文
共 50 条
  • [1] Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy
    Tom, Martin C.
    Reddy, Chandana A.
    Smile, Timothy D.
    Zhang, Ryan X.
    Ciezki, Jay P.
    Stephans, Kevin L.
    Mian, Omar Y.
    Klein, Eric A.
    Campbell, Steven
    Ulchaker, James
    Angermeier, Kenneth
    Tendulkar, Rahul D.
    BRACHYTHERAPY, 2020, 19 (01) : 43 - 50
  • [2] I-125 brachytherapy in low/intermediate risk prostate cancer according with NCCN and EAU guidelines
    Trigo, M. L.
    Fernandes, P.
    Garcia, S.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1616 - S1617
  • [3] High-risk prostate cancer treated with I-125 brachytherapy.
    Stockham, Abigail Lauren
    Reddy, Chandana A.
    Stephans, Kevin L.
    Ciezki, Jay P.
    Tendulkar, Rahul D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [4] I-125 LDR Brachytherapy in Patients with Low-risk Prostate Cancer - a retrospective Analysis of Patients
    Fels, F.
    Okonkwo, E.
    Schadt, T.
    Laschke, S.
    Loevey, G.
    Lansing, D.
    Grossmann, J. G.
    Freund, U.
    Steurer, R.
    Momm, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S87 - S87
  • [5] Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy
    Anna Thi Huyen Tran
    Mandall, Paula
    Swindell, Ric
    Hoskin, P. J.
    Bottomley, David Martin
    Logue, John Paul
    Wylie, James Pinson
    RADIOTHERAPY AND ONCOLOGY, 2013, 109 (02) : 235 - 240
  • [6] BIOCHEMICAL (PSA) FREE SURVIVAL AMONG 700 PROSTATE CANCER PATIENTS TREATED WITH I-125 BRACHYTHERAPY ONLY
    Matzkin, H.
    Stenger, A.
    Chen, J.
    Mabjeesh, N. J.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 310 - 310
  • [7] Radiation protection and dosimetry issues for patients with prostate cancer after I-125 low-dose-rate brachytherapy permanent implant
    Licciardello, Tiziana
    Feliciani, Giacomo
    Mazzotti, Giorgio
    Mostacci, Domiziano
    Sarnelli, Anna
    Menghi, Enrico
    BRACHYTHERAPY, 2021, 20 (01) : 272 - 278
  • [8] 125I low-dose-rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer
    Zhou, Zhien
    Yan, Weigang
    Zhou, Yi
    Zhang, Fuquan
    Li, Hanzhong
    Ji, Zhigang
    ONCOLOGY LETTERS, 2019, 18 (01) : 72 - 80
  • [9] Acute toxicity in low risk prostate cancer treated with low dose (125)I brachytherapy: Prospective analysis.
    Cabeza, A.
    Rodriguez, A.
    Caballero, P.
    Rosa de la, S.
    Leiva, O.
    Fernandez-Leton, P.
    Lopez, A.
    Cabello, E.
    Lanzos, E.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S250 - S251
  • [10] Outcomes of Gleason Score ≤8 among High Risk Prostate Cancer Treated with 125I Low Dose Rate Brachytherapy Based Multimodal Therapy
    Park, Dong Soo
    Gong, In Hyuck
    Choi, Don Kyung
    Hwang, Jin Ho
    Shin, Hyun Soo
    Oh, Jong Jin
    YONSEI MEDICAL JOURNAL, 2013, 54 (05) : 1207 - 1213
12345